NeurAxis, Inc.

Our Mission at NeurAxis is to provide solutions that create value and provide better and safer patient outcomes.

[NeurAxis, Inc. @NeurAxisInc]

Pain intensity is just one part of a patient's overall symptom burden. Evaluating pain frequency, severity, and duration can provide a more comprehensive assessment of treatment response.

In a randomized, double-blind, sham-controlled clinical trial, adolescents treated with IB-Stim® experienced statistically significant improvements in Pain Frequency-Severity-Duration (PFSD) composite scores compared with sham treatment. The difference between treatment groups increased over the course of the study, with the greatest separation observed at Week 3.

IB-Stim is FDA-cleared for patients ages 8 years and older with functional abdominal pain associated with irritable bowel syndrome (IBS) or functional dyspepsia.
In patients with functional dyspepsia, IB-Stim has also been shown to reduce associated nausea symptoms.

Reference:
Kovacic K, et al. Lancet Gastroenterology & Hepatology. 2017; 2:727-737. https://t.co/kzRHe125MY

Learn more: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit:https://t.co/ZjHKpZ88Dp

#ClinicalResearch #FunctionalAbdominalPain #FunctionalDyspepsia #Gastroenterologist #GutBrainConnection #EvidenceBasedMedicine #DGBI #PENFS

[NeurAxis, Inc. @NeurAxisInc]

For pediatric GI practices, IB-Stim® may be relevant when patients have tried multiple approaches and functional abdominal pain remains difficult to manage.
As a non-drug device, IB-Stim may offer another option to consider within an individualized treatment plan for appropriate patients.
IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies.
Learn more: https://t.co/DbI55tVsbO
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp
#PediatricGI #FunctionalAbdominalPain #IBStim

[NeurAxis, Inc. @NeurAxisInc]

For pediatric GI clinicians managing functional abdominal pain associated with IBS or functional dyspepsia, neuromodulation may offer a non-drug option to consider for appropriate patients.

IB-Stim® delivers percutaneous electrical nerve field stimulation (PENFS). Preclinical research has demonstrated that PENFS can modulate activity in central pain-processing regions, including the amygdala.¹

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies.

Learn more: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

Reference
Babygirija R, et al. Neuroscience. 2017;356:11-21.

#BrainGutAxis #PediatricGI #Neuromodulation

[NeurAxis, Inc. @NeurAxisInc]

For pediatric GI teams considering non-drug options, IB-Stim® provides an FDA-cleared device option for appropriate patients.

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies. In patients with functional dyspepsia, IB-Stim has also been shown to reduce associated nausea symptoms.

Learn more: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#IBStim #FunctionalAbdominalPain #PediatricGI

[NeurAxis, Inc. @NeurAxisInc]

When diagnostic evaluation supports a disorder of gut-brain interaction, the next challenge is often identifying appropriate treatment options.
For patients with functional abdominal pain associated with IBS or functional dyspepsia, IB-Stim® offers a non-drug treatment option that can be considered as part of an individualized care plan.
IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies.
Learn more: https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX
#FunctionalAbdominalPain #PediatricGI #BrainGutAxis

[NeurAxis, Inc. @NeurAxisInc]

For clinicians evaluating non-drug options for functional abdominal pain associated with IBS, published clinical evidence may help inform where IB-Stim® fits in the care pathway.
IB-Stim was evaluated in a randomized, double-blind, sham-controlled clinical trial involving adolescents with functional abdominal pain associated with IBS. By week 3, 59% of patients treated with IB-Stim achieved at least a 30% reduction in worst abdominal pain compared with 26% of patients receiving sham treatment.¹
Review the published clinical evidence behind IB-Stim.
Learn more: https://t.co/DbI55tVsbO
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp
Reference
Kovacic K, et al. Lancet Gastroenterology & Hepatology. 2017;2:727-737.
#ClinicalEvidence #PediatricGI #IBStim

[NeurAxis, Inc. @NeurAxisInc]

As neuromodulation, becomes a more frequent part of pediatric GI treatment conversations, IB-Stim® provides a non-drug option for appropriate patients with functional abdominal pain associated with IBS or functional dyspepsia.

IB-Stim delivers percutaneous electrical nerve field stimulation (PENFS) to branches of cranial nerves located in the ear. Preclinical research demonstrated modulation of activity within central pain-processing regions, including the amygdala.¹

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies.

Learn more: https://t.co/DbI55tW01m

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX

Reference
1. Babygirija R, et al. Neuroscience. 2017;356:11-21.
#BrainGutAxis #Neuromodulation #PediatricGI

[NeurAxis, Inc. @NeurAxisInc]

For patients with functional abdominal pain associated with IBS or functional dyspepsia, treatment planning often requires options beyond medication alone.

IB-Stim® offers a non-drug treatment option that may fit within individualized care plans for appropriate patients.

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia, used in conjunction with other therapies. In patients with functional dyspepsia, IB-Stim has also been shown to reduce associated nausea symptoms.

Learn more: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#PediatricGI #FunctionalAbdominalPain #IBStim

[NeurAxis, Inc. @NeurAxisInc]

Safety and tolerability remain important considerations in pediatric gastroenterology care.
In a randomized controlled trial evaluating IB-Stim®, no serious adverse events were reported. Reported events were mild and localized, including mild ear discomfort and adhesive sensitivity in less than 3% of patients.*

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia.

*Kovacic K et al. Lancet Gastroenterol Hepatol. 2017;2:727–737.

Learn more about IB-Stim:
https://t.co/DbI55tW01m

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit:
https://t.co/ZjHKpZ8GsX

#IBStim #ClinicalSafety #PediatricGI #FunctionalAbdominalPain #Neuromodulation #EvidenceBasedMedicine

[NeurAxis, Inc. @NeurAxisInc]

Functional abdominal pain associated with IBS and functional dyspepsia involves mechanisms within the brain-gut axis and central pain processing.
IB-Stim® delivers percutaneous electrical nerve field stimulation (PENFS) and is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and FD.
As pediatric GI care continues to evolve, mechanism-focused approaches remain an important part of clinical discussion.
Learn how IB-Stim works:
https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit:
https://t.co/ZjHKpZ8GsX
#IBStim #BrainGutAxis #PediatricGI #FunctionalAbdominalPain #Neuromodulation #DGBI

[NeurAxis, Inc. @NeurAxisInc]

In pediatric patients with functional dyspepsia, abdominal pain may present with associated nausea symptoms.
IB-Stim® is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with functional dyspepsia, including associated nausea symptoms in FD.

As pediatric gastroenterologists continue evaluating non-drug approaches within multidisciplinary care pathways, neuromodulation remains an important area of clinical interest.

Learn more about IB-Stim:
https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit:
https://t.co/ZjHKpZ88Dp

#IBStim #FunctionalDyspepsia #PediatricGI #BrainGutAxis #Neuromodulation #Gastroenterology

[NeurAxis, Inc. @NeurAxisInc]

NeurAxis is pleased to recognize the first patient treated with IB-Stim® at CHKD Pediatric Gastroenterology.

A special thank you to Melia Leisten, CPNP, and Caitlin Brewster, RN, for their role in supporting IB-Stim implementation for pediatric patients with functional abdominal pain.

IB-Stim is FDA-cleared for patients ages 8 and up with functional abdominal pain associated with IBS and functional dyspepsia. In patients with FD, IB-Stim has also been shown to reduce nausea symptoms.

We appreciate the work of dedicated providers who continue to evaluate evidence-based neuromodulation options within pediatric GI care.

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#IBStim #PediatricGI #FunctionalAbdominalPain #FunctionalDyspepsia #PediatricGastroenterology #Neuromodulation #BrainGutAxis #ChildrensHealth #CHKD

[NeurAxis, Inc. @NeurAxisInc]

Functional abdominal pain reflects dysregulation along the brain–gut axis, with central processing pathways (including the amygdala and vagal signaling) contributing to symptom perception.

In disorders of gut–brain interaction, these mechanisms are increasingly recognized as therapeutic targets rather than purely descriptive findings.

IB-Stim® delivers percutaneous electrical nerve field stimulation via auricular branches to modulate these pathways, offering a neuromodulation approach that can be incorporated into clinical management.

Learn how IB-Stim fits into your treatment pathway: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#IBStim #PediatricGI #FunctionalAbdominalPain #BrainGutAxis #Neuromodulation #IBS #FunctionalDyspepsia #NonDrugTherapy #Gastroenterology

[NeurAxis, Inc. @NeurAxisInc]

Adoption across leading pediatric gastroenterology centers continues to expand.
IB-Stim® is currently available at 9 of the top 10 U.S. children’s hospitals for gastroenterology, based on U.S. News & World Report rankings.

As neuromodulation becomes more integrated into care pathways, understanding where it fits in clinical practice is increasingly relevant.

Source: U.S. News & World Report Best Children’s Hospitals Rankings
https://t.co/uw5UiXXbqE

Learn how IB-Stim works: https://t.co/DbI55tW01m

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX

hashtag#IBStim hashtag#BrainGutAxis hashtag#Neuromodulation hashtag#PediatricGastroenterology hashtag#GIHealth

[NeurAxis, Inc. @NeurAxisInc]

In patients with functional dyspepsia, IB-Stim® has also been shown to reduce nausea symptoms.
IB-Stim is an FDA-cleared neuromodulation device for patients ages 8 and older with functional abdominal pain associated with IBS and functional dyspepsia. It stimulates auricular nerve branches connected to central pain pathways.
Learn how IB-Stim works: https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX
#IBStim #PediatricGI #FunctionalAbdominalPain #IBS #FunctionalDyspepsia #Neuromodulation #BrainGutAxis #EvidenceBasedMedicine #Gastroenterology

[NeurAxis, Inc. @NeurAxisInc]

In a randomized, sham-controlled trial, a significantly higher proportion of patients receiving IB-Stim® reported overall symptom improvement compared to sham by week 3, based on the Symptom Response Scale.

This endpoint reflects changes in patient-reported outcomes across multiple symptom domains.

Reference: Kovacic K et al. Lancet Gastroenterol Hepatol. 2017;2:727–737.

Learn more: https://t.co/DbI55tVsbO

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#IBStim #PediatricGI #FunctionalAbdominalPain #IBS #FunctionalDyspepsia #Neuromodulation #BrainGutScience #NonDrugOption #Gastroenterology

[NeurAxis, Inc. @NeurAxisInc]

We’re excited to see the continued expansion of IB-Stim® training across leading pediatric GI programs.

Congratulations to Dr. Tracie Wong (right) and Dr. Shamila Zawahir (left) at Joseph M. Sanzari Children's Hospital of @hackensackmeridianhealth for recently completing their training for IB-Stim and expanding access to a drug-free treatment option for children and adolescents with abdominal pain associated with IBS and functional dyspepsia.

IB-Stim, a percutaneous electrical nerve field stimulation device (PENFS), is indicated for patients 8 and older who suffer from functional abdominal pain due to IBS, functional dyspepsia (FD), and FD-related nausea symptoms.

For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ88Dp

#PediatricGI #IBStim #FunctionalAbdominalPain #FunctionalDyspepsia #IBS #Gastroenterology #PediatricHealthcare #Neuromodulation

[NeurAxis, Inc. @NeurAxisInc]

IBS awareness includes recognizing that functional abdominal pain associated with IBS may involve altered signaling along the brain-gut axis rather than structural disease.
This distinction can influence how pediatric patients are evaluated and how care plans are developed, particularly for those who have not responded to initial therapies.
During IBS Awareness Month, continued focus on mechanism-based understanding may support more informed clinical decision-making.
IB-Stim® is FDA-cleared for patients ages 8 years and older with functional abdominal pain associated with IBS and functional dyspepsia. In patients with functional dyspepsia, IB-Stim has also been shown to address associated nausea symptoms.
Explore the mechanism: https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX
#IBSAwarenessMonth #PediatricGastroenterology #FunctionalAbdominalPain #IBS #Neuromodulation #BrainGutAxis #GIHealth #IBSAwarenessMonth #MoreThanAStomachache

[NeurAxis, Inc. @NeurAxisInc]

April is IBS Awareness Month, a time to highlight the clinical complexity of disorders of gut-brain interaction and their impact on pediatric patients.
Functional abdominal pain associated with IBS remains a common reason for pediatric GI visits, with management approaches varying based on underlying mechanisms and patient presentation.
For children and adolescents, evaluating central pain processing may be an important component of care.
IB-Stim® is FDA-cleared for patients 8 years and older with functional abdominal pain associated with IBS and functional dyspepsia. This non-drug, neuromodulation device can be incorporated into care plans for appropriate patients.
Learn more: https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX
#IBSAwarenessMonth #PediatricGI #FunctionalAbdominalPain #IBS #BrainGutAxis #Gastroenterology #DGBI #IBSAwarenessMonth #MoreThanAStomachache

[NeurAxis, Inc. @NeurAxisInc]

IB-Stim is a percutaneous electrical nerve field stimulator system intended for patients ages 8 years and older with functional abdominal pain associated with IBS and FD.
It is used 120 hours per week for four consecutive weeks as an aid in the reduction of pain when combined with other therapies for IBS and FD.
In patients with FD, IB-Stim has also been shown to reduce nausea symptoms.
See how IB-Stim integrates into pediatric GI care: https://t.co/DbI55tW01m
For important IB-Stim information, including indications, precautions, IFU, and contraindications, visit: https://t.co/ZjHKpZ8GsX
#IBStim #PediatricGI #FunctionalAbdominalPain #StandardOfCare #Neuromodulation #IBS #FunctionalDyspepsia #Gastroenterology #NonDrugOption